Medtronic, a global leader in medical technology, has officially announced the appointment of Lara Barghout as the new President of its Interventional Cardiology Therapies (ICT) business. Barghout, a seasoned executive with over two decades of experience in the medtech sector, joins the company following a high-profile tenure as the CEO of Recor Medical. Her transition to Medtronic marks a significant leadership shift within the cardiovascular device industry, particularly as the company seeks to consolidate its position in the competitive markets for structural heart, coronary, and hypertension management.
The Interventional Cardiology Therapies division at Medtronic is a critical component of the company’s broader cardiovascular portfolio. This specific operating unit is responsible for overseeing several of Medtronic’s most innovative and commercially vital product lines, including transcatheter valves, coronary stents, and the burgeoning field of renal denervation (RDN). Barghout’s appointment comes at a pivotal time for Medtronic as it navigates a complex regulatory landscape and a period of internal organizational restructuring designed to enhance operational efficiency and accelerate innovation.
A Strategic Hire from a Key Competitor
Barghout’s move to Medtronic is particularly noteworthy because of her recent history at Recor Medical, a subsidiary of Otsuka Medical Devices. During her time as CEO of Recor, which began in January 2023, she oversaw a landmark achievement: the U.S. Food and Drug Administration (FDA) approval of the Paradise Ultrasound Renal Denervation System. This approval, granted in early November 2023, made Recor’s device the first-ever RDN treatment for hypertension to be cleared for use in the United States.
The race for FDA approval in the RDN space was a closely watched contest between Recor and Medtronic. For years, both companies had been developing technologies to treat uncontrolled hypertension by disrupting the nerves in the renal arteries, which are known to play a role in high blood pressure. While Recor utilized ultrasound energy, Medtronic developed the Symplicity Spyral system, which uses radiofrequency energy.
Although Medtronic had been a pioneer in the RDN space for over a decade, Recor managed to secure the first regulatory nod by a matter of weeks. Medtronic’s Symplicity Spyral system received FDA approval shortly thereafter in late November 2023, but only after a contentious and divided advisory panel vote. The panel had expressed concerns regarding the efficacy of Medtronic’s system compared to the robust safety profile it demonstrated. By hiring the executive who successfully led Recor through this competitive regulatory finish line, Medtronic is signaling a commitment to aggressive growth and strategic dominance in the hypertension management sector.
The Scope of the Interventional Cardiology Therapies Business
The ICT unit that Barghout will lead is one of four specialized divisions within Medtronic’s newly reorganized cardiovascular portfolio. In an effort to streamline decision-making and foster more specialized expertise, Medtronic recently split its cardiovascular business into Electrophysiology Therapies, CardioVascular Surgery, Peripheral Vascular Health, and Interventional Cardiology Therapies.
Under Barghout’s leadership, the ICT division will focus on three primary pillars:
- Structural Heart: This includes the Evolut TAVR (Transcatheter Aortic Valve Replacement) platform, which competes directly with Edwards Lifesciences. As the population ages, the demand for minimally invasive valve replacements continues to grow, making this a high-stakes area for Medtronic.
- Coronary: This segment encompasses the company’s portfolio of drug-eluting stents, balloons, and catheters used to treat coronary artery disease. It remains a foundational revenue driver for the cardiovascular group.
- Hypertension Management: Centered on the Symplicity Spyral RDN system, this pillar represents one of the most significant growth opportunities for the company. With billions of people globally suffering from hypertension, the market for a device-based treatment for patients who do not respond to traditional medication is immense.
In an official statement, Medtronic emphasized that Barghout’s "global, future-ready mindset" would be essential for the integrated ICT team. The company noted that her leadership would be instrumental in elevating breakthrough innovations and digitally transforming the "cath lab" (catheterization laboratory), where these interventional procedures are performed.
Professional Background and Leadership Trajectory
Lara Barghout’s career is characterized by a consistent focus on scaling global medtech businesses and managing complex medical portfolios. Prior to her role at Recor Medical, she served as the Senior Vice President and Head of Advanced Therapies at Siemens Healthineers. At Siemens, she was responsible for overseeing a wide range of imaging and therapeutic technologies, experience that Medtronic likely views as vital for its goal of integrating digital and AI-driven tools into the interventional cardiology workflow.
Her resume also includes significant executive experience at Terumo Cardiovascular, where she held various leadership roles focused on global commercial strategy and business development. This background provides her with a holistic view of the cardiovascular market, ranging from the technical nuances of surgical tools to the high-level strategic requirements of global commercialization.
Barghout’s departure from Recor in February 2024 and her subsequent move to Medtronic follow a period of transition for the latter’s leadership team. The ICT division has seen several high-level departures in recent months. Jason Weidman, the former Senior Vice President and President of Coronary and Renal Denervation, left Medtronic in the spring to take the helm as CEO of Teleflex. Additionally, Jason Fontana, who served as the Vice President and General Manager of Renal Denervation, recently announced his departure from the company. Barghout’s arrival provides much-needed stability and a fresh perspective to a leadership team that is tasked with launching new products in a post-pandemic market.
The Evolution of the Cath Lab and Digital Transformation
One of the key themes mentioned by Medtronic in the wake of Barghout’s appointment is the "digital transformation of the cath lab." This reflects a broader trend in the medical device industry where hardware—such as stents and valves—is increasingly being integrated with software, imaging, and artificial intelligence.
The modern cath lab is no longer just a room for manual procedures; it is becoming a data-rich environment where real-time analytics can guide physicians toward better patient outcomes. Medtronic has been investing heavily in digital health, and Barghout’s experience at Siemens Healthineers—a leader in medical imaging and digital health solutions—positions her as a uniquely qualified leader to bridge the gap between traditional interventional devices and the digital future. This transformation is expected to involve the use of AI to predict patient risks, optimize device placement, and improve the efficiency of hospital workflows.
Market Context and Global Implications
The global cardiovascular device market is projected to reach over $80 billion by the end of the decade, driven by the increasing prevalence of heart disease and the shift toward minimally invasive procedures. Medtronic, as the world’s largest pure-play medical device company, is under constant pressure to maintain its market share against rivals like Boston Scientific, Abbott Laboratories, and Edwards Lifesciences.
In the specific realm of hypertension, the stakes are even higher. According to the World Health Organization, an estimated 1.28 billion adults aged 30–79 years worldwide have hypertension, and nearly half of them are unaware of their condition. More importantly, only about one in five adults with hypertension have it under control. The introduction of RDN therapy represents a potential paradigm shift in how chronic high blood pressure is managed.
By bringing Barghout on board, Medtronic is not just hiring a manager; it is acquiring the expertise of someone who has successfully navigated the "first-to-market" hurdles. This is crucial as Medtronic looks to expand the adoption of Symplicity Spyral across global markets, including Europe and Asia, where healthcare systems are increasingly focused on the long-term cost-effectiveness of device-based therapies versus lifelong medication adherence.
Analysis of Future Challenges
Despite the strengths Barghout brings to the table, her tenure will not be without challenges. The ICT division must address several critical issues in the coming years:
- Clinical Evidence and Adoption: While the FDA has approved RDN, the medical community remains cautious. Barghout will need to oversee the generation of long-term clinical data to convince skeptical cardiologists and primary care physicians that RDN is a viable and necessary alternative to pharmacotherapy.
- Reimbursement: Securing favorable reimbursement rates from insurance providers and government health programs is essential for the commercial success of new technologies like RDN and advanced TAVR valves.
- Supply Chain and Macroeconomics: Like all global manufacturers, Medtronic continues to face headwinds from supply chain volatility and inflationary pressures. Maintaining healthy margins in the ICT division while investing in R&D will be a delicate balancing act.
- Competitive Pressure: Competitors are not standing still. With Recor Medical now under new leadership and other players entering the structural heart space, Medtronic must maintain a rapid pace of iteration and innovation.
Conclusion
The appointment of Lara Barghout as President of Interventional Cardiology Therapies is a strategic masterstroke for Medtronic. By recruiting a leader who has already demonstrated the ability to secure historic regulatory wins in the same therapeutic space, Medtronic is reinforcing its intent to lead the next generation of cardiovascular care. As the company continues to integrate its cardiovascular divisions and push toward a digitally enabled future, Barghout’s experience in scaling businesses and her deep understanding of the global medtech landscape will be vital assets. The industry will be watching closely to see how her leadership influences the commercial trajectory of Medtronic’s most ambitious cardiology projects.
